Literature DB >> 20470797

Novel vaccine prime and selective BCG boost: a new tuberculosis vaccine strategy for infants of HIV-infected mothers.

Mark Hatherill, Hassan Mahomed, Willem Hanekom.   

Abstract

Novel tuberculosis vaccination strategies hinge on BCG priming, yet newborn BCG vaccination may cause BCG disease in HIV-infected infants. Viral-vectored or subunit prime vaccine, followed by delayed BCG boost only for HIV-uninfected infants, may be a safe alternative for all newborns, regardless of maternal HIV infection. This approach should be tested using new tuberculosis vaccine candidates. If safety and immunogenicity of a novel vaccine prime is established in infants of HIV-infected mothers, for whom newborn BCG carries unacceptable risk, this strategy might then be compared to conventional BCG prime and viral-vectored or subunit boost, and BCG alone, in HIV-unexposed infants. (c) 2010 Elsevier Ltd. All rights reserved.

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 20470797     DOI： 10.1016/j.vaccine.2010.04.088

Source DB:  PubMed          Journal:  Vaccine        ISSN： 0264-410X            Impact factor:   3.641


  5 in total

1.  Bacillus Calmette-Guérin vaccination using a microneedle patch.

Authors:  Yasuhiro Hiraishi; Subhadra Nandakumar; Seong-O Choi; Jeong Woo Lee; Yeu-Chun Kim; James E Posey; Suraj B Sable; Mark R Prausnitz
Journal:  Vaccine       Date:  2011-01-28       Impact factor: 3.641

Review 2.  Prime-boost approaches to tuberculosis vaccine development.

Authors:  Neha Dalmia; Alistair J Ramsay
Journal:  Expert Rev Vaccines       Date:  2012-10       Impact factor: 5.217

3.  Formulation of a mmaA4 gene deletion mutant of Mycobacterium bovis BCG in cationic liposomes significantly enhances protection against tuberculosis.

Authors:  Steven C Derrick; Dee Dao; Amy Yang; Kris Kolibab; William R Jacobs; Sheldon L Morris
Journal:  PLoS One       Date:  2012-03-19       Impact factor: 3.240

4.  Boosting BCG-primed responses with a subunit Apa vaccine during the waning phase improves immunity and imparts protection against Mycobacterium tuberculosis.

Authors:  Subhadra Nandakumar; Sunil Kannanganat; Karen M Dobos; Megan Lucas; John S Spencer; Rama Rao Amara; Bonnie B Plikaytis; James E Posey; Suraj B Sable
Journal:  Sci Rep       Date:  2016-05-13       Impact factor: 4.379

5.  Safety and Immunogenicity of Newborn MVA85A Vaccination and Selective, Delayed Bacille Calmette-Guerin for Infants of Human Immunodeficiency Virus-Infected Mothers: A Phase 2 Randomized, Controlled Trial.

Authors:  Elisa Nemes; Anneke C Hesseling; Michele Tameris; Katya Mauff; Katrina Downing; Humphrey Mulenga; Penelope Rose; Marieke van der Zalm; Sharon Mbaba; Danelle Van As; Willem A Hanekom; Gerhard Walzl; Thomas J Scriba; Helen McShane; Mark Hatherill
Journal:  Clin Infect Dis       Date:  2018-02-01       Impact factor: 9.079
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.